Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Nov 7;35(42):2980-7.
doi: 10.1093/eurheartj/ehu052. Epub 2014 Feb 25.

Association of exhaled carbon monoxide with subclinical cardiovascular disease and their conjoint impact on the incidence of cardiovascular outcomes

Affiliations
Observational Study

Association of exhaled carbon monoxide with subclinical cardiovascular disease and their conjoint impact on the incidence of cardiovascular outcomes

Susan Cheng et al. Eur Heart J. .

Abstract

Aims: Whereas endogenous carbon monoxide (CO) is cytoprotective at physiologic levels, excess CO concentrations are associated with cardiometabolic risk and may represent an important marker of progression from subclinical to clinical cardiovascular disease (CVD).

Methods and results: In 1926 participants of the Framingham Offspring Study (aged 57 ± 10 years, 46% women), we investigated the relationship of exhaled CO, a surrogate of blood CO concentration, with both prevalent subclinical CVD and incident clinical CVD events. Presence of subclinical CVD was determined using a comprehensive panel of diagnostic tests used to assess cardiac and vascular structure and function. Individuals with the highest (>5 p.p.m.) compared with lowest (≤4 p.p.m.) CO exposure were more likely to have subclinical CVD [odds ratios (OR): 1.67, 95% CI: 1.32-2.12; P < 0.001]. During the follow-up period (mean 5 ± 3 years), 193 individuals developed overt CVD. Individuals with both high CO levels and any baseline subclinical CVD developed overt CVD at an almost four-fold higher rate compared with those with low CO levels and no subclinical disease (22.1 vs. 6.3%). Notably, elevated CO was associated with incident CVD in the presence [hazards ration (HR): 1.83, 95% CI: 1.08-3.11; P = 0.026] but not in the absence (HR: 0.80, 95% CI: 0.42-1.53; P = 0.51) of subclinical CVD (Pinteraction = 0.019). Similarly, subclinical CVD was associated with incident CVD in the presence of high but not low CO exposure.

Conclusion: Our findings in a community-based sample suggest that elevated CO is a marker of greater subclinical CVD burden and, furthermore, a potential key component in the progression from subclinical to clinical CVD.

Keywords: Carbon monoxide; Cardiovascular outcomes; Subclinical vascular disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multivariable-adjusted spline graph displaying the relation of carbon monoxide exposure with prevalent subclinical cardiovascular disease. Bold lines show the association between average exhaled carbon monoxide and presence of subclinical disease; upper and lower 95% confidence limits are plotted as dashed lines, with knots corresponding to carbon monoxide categories (where knots are the points connecting adjoining pieces of the polynomial spline function).
Figure 2
Figure 2
Spline graph displaying the relation of carbon monoxide exposure with incident cardiovascular events, adjusted for baseline presence of subclinical cardiovascular disease. Bold lines show the association between average exhaled carbon monoxide and risk for cardiovascular events; upper and lower 95% confidence limits are plotted as dashed lines, with knots corresponding to carbon monoxide categories.
Figure 3
Figure 3
The cumulative incidence of cardiovascular events is shown over the follow-up period by carbon monoxide category.

References

    1. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med. 2002;7:195–202. - PubMed
    1. Wang X, Wang Y, Kim HP, Nakahira K, Ryter SW, Choi AM. Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation. J Biol Chem. 2007;282:1718–1726. - PubMed
    1. Ndisang JF, Tabien HE, Wang R. Carbon monoxide and hypertension. J Hypertens. 2004;22:1057–1074. - PubMed
    1. Chan KH, Ng MK, Stocker R. Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2011;120:493–504. - PubMed
    1. Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. Am J Respir Cell Mol Biol. 2007;36:175–182. - PMC - PubMed

Publication types